Jubilant Pharmova Subsidiary Faces ₹53.37 Crore Tax Disallowance

NOIDA, India — Jubilant Pharmova Limited announced on Tuesday that its wholly owned subsidiary, Jubilant Biosys Limited, has received a tax rectification order from the jurisdictional assessing officer in Noida. The regulatory order, dated June 29, 2026, disallows a claim of brought-forward operational losses amounting to ₹53.37 crore for the assessment year 2019-20.

The pharmaceutical firm stated it will contest the ruling, emphasizing that the adjustment bypasses established legal facts and historical submissions. The development highlights ongoing scrutiny of corporate tax structures and legacy compliance balances within India’s pharmaceutical and bio-services landscape.

Assessing Officer Disallows Brought-Forward Losses

The dispute stems from an amendment to an assessment originally processed under Section 143(1) of the Income-tax Act, 1961. The order was executed by the Deputy Commissioner of Income Tax (DCIT) in Noida, covering Assessment Year 2019-20, which relates to the Financial Year 2018-19 cycle.

According to Jubilant Pharmova’s compliance notification issued to Indian stock exchanges, the rectification order specifically targets the subsidiary’s accounting of past operational losses. By disallowing the ₹53.37 crore adjustment, the tax authority essentially re-estimates the net taxable baseline for the designated period, potentially altering tax liabilities if upheld by regional tribunals.

Corporate Defense and Appellate Strategy

In its official regulatory dispatch filed under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015, Jubilant Pharmova detailed its intent to secure an administrative reversal. Corporate compliance executives confirmed that the order was officially acknowledged internally at 12:20 PM IST on June 30, 2026.

Management noted that it considers the current adjustment flawed, arguing that local authorities executed the order by ignoring the comprehensive provisions of law and contentions previously filed by the subsidiary. Consequently, Jubilant Biosys is preparing to escalate the dispute by launching an official administrative appeal before the National Faceless Appeal Centre (NFAC).

Official Sources Section

The material information in this report was prepared and verified by Naresh Kapoor, Company Secretary for Jubilant Pharmova Limited. The official corporate documentation was submitted simultaneously to the BSE Limited and the National Stock Exchange of India Limited for public transparency.

Quote Section

"The Company believes that the impugned tax adjustment has been made ignoring the facts and contentions of the Company and provisions of law," stated Naresh Kapoor, Company Secretary, in the signed corporate disclosure.

"The Company is in the process of taking the necessary action to file an appeal before the Appellate Authority [National Faceless Appeal Centre (NFAC)] against the impugned order. Post adjudication by Appellate authority, impugned adjustment is likely to get deleted," the filing stated.

Why It Matters

Tax disputes centering on substantial corporate loss deductions can create near-term volatility for public companies, as investors weigh potential back-tax obligations. However, because the company expects total relief upon review by higher appellate bodies, it does not currently anticipate an immediate material adverse impact on its cash flows or regular pharmaceutical development work.

Key Facts at a Glance

• The Order: DCIT Noida has disallowed a tax deduction claim totaling ₹53.37 crore for Jubilant Biosys Limited.

• The Context: The rectification involves an amendment under Section 143(1) for Assessment Year 2019-20.

• The Counter-Strategy: Jubilant Pharmova is approaching the National Faceless Appeal Centre (NFAC) to reverse the disallowance.

• Financial Projection: Executive leadership expects the adjustment to be completely deleted upon independent review, mitigating operational risks.

FAQ Section

Q: What is a Section 143(1) rectification order?

A: This refers to an amendment or correction made by an Income Tax Assessing Officer regarding automated summaries or preliminary processing notices, adjusting computational errors or disallowed claims on filed returns.

Q: Who is Jubilant Biosys Limited?

A: Jubilant Biosys is a wholly owned subsidiary of Jubilant Pharmova Limited that provides contract research and functional development solutions to global pharmaceutical and biotech innovators.

Q: Will this ongoing tax dispute halt operations or production lines?

A: No. The company stated it expects favorable adjustments from first-level appellate authorities and does not project any material disruptions to its ongoing business operations.

Sources: Regulation 30 Regulatory Filing published via BSE Limited and National Stock Exchange of India Limited., Media Relations and Corporate Disclosures via Jubilant Pharmova Limited.